Entering text into the input field will update the search result below

Viatris stands out amid selloff in generic drugmakers

Mar. 05, 2022 12:00 PM ETViatris Inc. (VTRS)TEVA, AMPHBy: Dulan Lokuwithana, SA News Editor67 Comments

Buy or sell dices, investing and trading concept.

lcs813/iStock via Getty Images

The shares of Viatris (NASDAQ:VTRS) and Teva (VTRS) have well underperformed the broader market over the past 12 months. Weighed down by pricing pressure and opioid-related liabilities, Teva (NYSE:TEVA) has lost ~25%, while high

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.